ADEBRELIMAB (SHR-1316)

Clinical trials for ADEBRELIMAB (SHR-1316) explained in plain language.

Never miss a new study

Get alerted when new ADEBRELIMAB (SHR-1316) trials appear

Sign up with your email to follow new studies for ADEBRELIMAB (SHR-1316), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo therapy shows promise for untreatable liver cancer

Disease control Not yet recruiting

This study tests a new drug combination for people with advanced liver cancer that cannot be surgically removed. Participants will receive two immunotherapy drugs (adebrelimab and low-dose bevacizumab) along with a two-step procedure that delivers chemotherapy directly to the liv…

Matched conditions: ADEBRELIMAB (SHR-1316)

Phase: PHASE2 • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control

Last updated May 15, 2026 11:54 UTC

ADEBRELIMAB (SHR-1316)

Get alerted when new ADEBRELIMAB (SHR-1316) trials appear

New combo therapy shows promise for untreatable liver cancer